

Daniele Generali

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/479521/daniele-general-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

5,587
citations

36
h-index

70
g-index

193
ext. papers

6,681
ext. citations

5.8
avg, IF

5.38
L-index

#	Paper	IF	Citations
172	Abstract P4-10-12: The relevance of chemobrain in breast cancer survivors: An Italian exploratory study to measure incidence and psycho-social impact. <i>Cancer Research</i> , 2022 , 82, P4-10-12-P4-10-12	10.1	
171	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry.. <i>European Journal of Cancer</i> , 2022 , 170, 10-16	7.5	1
170	Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2951	5.1	7
169	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , 2021 , 22, 1669-1680	21.7	20
168	BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. <i>Frontiers in Oncology</i> , 2021 , 11, 772052	5.3	0
167	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211053416	5.4	0
166	p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. <i>Molecules</i> , 2021 , 26,	4.8	2
165	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	4
164	Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 641449	5.7	6
163	Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 433-440	10.5	18
162	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021 , 27, 3443-3455 ²	12.9	
161	Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 455-465	4.4	0
160	CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6	21
159	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 149, 134-152	7.5	13
158	Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. <i>Frontiers in Oncology</i> , 2021 , 11, 686776	5.3	3
157	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021 , 150, 190-202	7.5	14
156	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 443-452	9.7	8

155	Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
154	Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer. <i>Cells</i> , 2021 , 10,	7.9	9
153	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	4
152	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
151	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1089-1097	9.7	25
150	Mutant p53 as an Antigen in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
149	The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	25
148	Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste. <i>Updates in Surgery</i> , 2020 , 72, 89-96	2.9	1
147	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020 , 235, 7900-7910	7	11
146	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. <i>Oncotarget</i> , 2020 , 11, 2172-2181	3.3	1
145	Early Changes of the Standardized Uptake Values (SUV) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
144	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Cancer Discovery</i> , 2020 ,	24.4	96
143	Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 421-431	4.4	5
142	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020 , 15, 22-27	2.4	
141	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020 , 146, 1917-1929	7.5	3
140	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , 2019 , 20, 1360-1369	21.7	68
139	Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. <i>Scientific Reports</i> , 2019 , 9, 13014	4.9	36
138	Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. <i>Cells</i> , 2019 , 8,	7.9	70

137	New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e534-e535	3.3	
136	Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. <i>PLoS ONE</i> , 2019 , 14, e0219566	3.7	11
135	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. <i>PLoS ONE</i> , 2019 , 14, e0220644	3.7	5
134	Avelumab in gastric cancer. <i>Immunotherapy</i> , 2019 , 11, 759-768	3.8	8
133	Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. <i>Cell Death and Disease</i> , 2019 , 10, 534	9.8	48
132	Granular cell tumor of the breast: a multidisciplinary challenge. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 144, 102828	7	7
131	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 134, 39-45	7	129
130	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 560-567	9.7	137
129	Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. <i>Medical Oncology</i> , 2018 , 35, 29	3.7	7
128	The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 4287-4292	4.7	43
127	Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 601-606	4.9	3
126	Lenvatinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 507-512	5.9	6
125	The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 72	12.8	40
124	Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?. <i>Clinical and Experimental Medicine</i> , 2018 , 18, 15-20	4.9	30
123	Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 321-330	4.4	56
122	Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. <i>Investigational New Drugs</i> , 2018 , 36, 1133-1137	4.3	14
121	Familial aggregation of gastric cancer with microsatellite instability. <i>Acta Chirurgica Belgica</i> , 2018 , 118, 287-293	0.9	2
120	Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. <i>Cells</i> , 2018 , 7,	7.9	32

119	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer. <i>Current Pharmaceutical Design</i> , 2018 , 24, 171-177	3.3	36
118	Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018 , 23, 298-299	1.5	
117	PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene. <i>Advances in Clinical and Experimental Medicine</i> , 2018 , 27, 963-969	1.8	13
116	Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. <i>Oncotarget</i> , 2018 , 9, 22332-22339	3.3	11
115	Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. <i>Oncotarget</i> , 2018 , 9, 24707-24717	3.3	12
114	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥65 years: new lessons for clinical practice from the EVA study. <i>Oncotarget</i> , 2018 , 9, 31877-31887	3.3	2
113	Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?. <i>World Journal of Clinical Oncology</i> , 2018 , 9, 26-32	2.5	13
112	Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. <i>British Journal of Cancer</i> , 2018 , 119, 1487-1494	8.7	15
111	Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer. <i>Lancet Oncology, The</i> , 2018 , 19, 1270-1272	21.7	4
110	Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 18-21	7	3
109	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017 , 75, 245-258	7.5	66
108	Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. <i>Cancer Investigation</i> , 2017 , 35, 187-194	2.1	9
107	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLETT Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. <i>Oncologist</i> , 2017 , 22, 648-654	5.7	8
106	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017 , 34, 119	3.7	26
105	Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. <i>Tumor Biology</i> , 2017 , 39, 1010428317695023	2.9	41
104	Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification. <i>Cancer Investigation</i> , 2017 , 35, 325-332	2.1	4
103	CDK4/6 inhibitors in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 208-214	7	30
102	Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis. <i>Investigational New Drugs</i> , 2017 , 35, 518-523	4.3	9

101	Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?. <i>Immunotherapy</i> , 2017 , 9, 25-32	3.8	6
100	Advances in systemic therapy for malignant mesothelioma: future perspectives. <i>Future Oncology</i> , 2017 , 13, 2083-2101	3.6	1
99	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , 2017 , 86, 257-265	7.5	21
98	Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer. <i>OncoTargets and Therapy</i> , 2017 , 10, 3811-3815	4.4	4
97	Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma. <i>Research and Reports in Urology</i> , 2017 , 9, 65-69	1.3	4
96	Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis. <i>Medical Oncology</i> , 2017 , 34, 166	3.7	2
95	Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis. <i>European Urology</i> , 2017 , 72, 1027-1028	10.2	0
94	Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?. <i>Future Oncology</i> , 2017 , 13, 2473-2477	3.6	2
93	PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy. <i>EBioMedicine</i> , 2017 , 22, 18-19	8.8	3
92	Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 371-375	3.3	0
91	Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 . <i>European Urology</i> , 2017 , 71, e55	10.2	
90	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. <i>Future Oncology</i> , 2017 , 13, 2791-2797	3.6	19
89	Isolated Testicular Metastasis from Prostate Cancer. <i>American Journal of Case Reports</i> , 2017 , 18, 887-889	1.3	7
88	Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma. <i>Genes and Cancer</i> , 2017 , 8, 495-496	2.9	7
87	Efficacy and safety of T-DM1 in the common-practice of HER2+ advanced breast cancer setting: a multicenter study. <i>Oncotarget</i> , 2017 , 8, 64481-64489	3.3	15
86	Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. <i>Oncotarget</i> , 2017 , 8, 78870-78881	3.3	4
85	Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2017 , 114, 103-105	5.9	1
84	Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. <i>Cancer Biology and Therapy</i> , 2016 , 17, 883-8	4.6	5

83	Apatinib in metastatic gastric cancer: can paclitaxel make the difference?. <i>Anti-Cancer Drugs</i> , 2016 , 27, 809	2.4	3
82	Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. <i>Histopathology</i> , 2016 , 68, 367-77	7.3	13
81	Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035 : Corticosteroid-associated Adverse Events in A Phase II study of olaparib in breast cancer patients: biological evaluation from a window of opportunity trial. <i>Future Oncology</i> , 2016 , 12, 2189-93	10.2	2
80	Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient. <i>Anti-Cancer Drugs</i> , 2016 , 27, 470-3	2.4	3
79	Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. <i>Cancer Letters</i> , 2016 , 372, 187-91	9.9	100
78	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. <i>Tumor Biology</i> , 2016 , 37, 127-40	2.9	8
77	Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 101, 12-20	7	30
76	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. <i>International Journal of Hyperthermia</i> , 2016 , 32, 298-310	3.7	21
75	High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 475-81	4.7	6
74	Current challenges in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 211-21	7	27
73	Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?. <i>Current Cancer Drug Targets</i> , 2016 , 16, 209-14	2.8	3
72	Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines. <i>PLoS ONE</i> , 2016 , 11, e0145647	3.7	14
71	No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials. <i>Clinical Lung Cancer</i> , 2016 , 17, 334-340	4.9	10
70	Apatinib for the treatment of gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 887-92	4.2	38
69	New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 108, 62-68	7	2
68	Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials. <i>Medicine (United States)</i> , 2016 , 95, e4636	1.8	4
67	A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers. <i>Clinical Breast Cancer</i> , 2016 , 16, e57-9	3	4
66			

65	Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 102, 82-8	7	26
64	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , 2016 , 61, 111-21	7.5	41
63	Ibrutinib: from bench side to clinical implications. <i>Medical Oncology</i> , 2015 , 32, 225	3.7	8
62	Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1 α and Relation to Clinical Response. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 64-6	4.8	4
61	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 95-117	4.4	25
60	High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 70-5	4.8	11
59	Breast cancer circulating biomarkers: advantages, drawbacks, and new insights. <i>Tumor Biology</i> , 2015 , 36, 6653-65	2.9	28
58	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015 , 35 Suppl, S276-S304	12.7	179
57	Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 32-5	4.8	6
56	Gene expression profiling of circulating tumor cells in breast cancer. <i>Clinical Chemistry</i> , 2015 , 61, 278-89	5.5	18
55	Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 689-702	3.5	9
54	RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 76-80	4.8	3
53	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 1-3	4.8	
52	Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. <i>Future Oncology</i> , 2015 , 11, 431-8	3.6	15
51	Broad targeting of angiogenesis for cancer prevention and therapy. <i>Seminars in Cancer Biology</i> , 2015 , 35 Suppl, S224-S243	12.7	314
50	Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?. <i>Oncoscience</i> , 2015 , 2, 567-9	0.8	1
49	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. <i>Oncotarget</i> , 2015 , 6, 28173-82	3.3	20
48	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 248-54	11.2	21

47	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014 , 15, 406-14	21.7	566
46	Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 113-21	4.4	13
45	Inhibitors of Tumor Angiogenesis 2014 , 275-317		1
44	Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - moving beyond pathological complete response. <i>Breast</i> , 2014 , 23, 188-92	3.6	6
43	Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 665-78	6.4	8
42	ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. <i>Oncotarget</i> , 2014 , 5, 6633-46	3.3	54
41	Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use. <i>Tumor Biology</i> , 2014 , 35, 8461-70	2.9	20
40	Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 67-78	4.4	48
39	Gene expression profiling in breast cancer: a clinical perspective. <i>Breast</i> , 2013 , 22, 109-120	3.6	56
38	The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. <i>Clinical Cancer Research</i> , 2013 , 19, 5740-8	12.9	15
37	Triple negative breast cancers have a reduced expression of DNA repair genes. <i>PLoS ONE</i> , 2013 , 8, e66243	3.7	27
36	Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. <i>Tumori</i> , 2013 , 99, 596-600	1.7	2
35	Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. <i>Annals of Surgical Oncology</i> , 2012 , 19, 3257-63	3.1	33
34	Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. <i>Cancer Letters</i> , 2012 , 323, 77-87	9.9	66
33	Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. <i>Cancer Treatment Reviews</i> , 2012 , 38, 689-97	14.4	208
32	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2766-71	11.5	156
31	Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1505-15	5.4	12
30	Enzalutamide in prostate cancer after chemotherapy. <i>New England Journal of Medicine</i> , 2012 , 367, 2448; author reply 2448-9	59.2	7

29	Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2012 , 166, 451-8	6.5	104
28	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1 and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. <i>Breast Cancer Research</i> , 2011 , 13, R16	8.3	21
27	Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. <i>Clinical Breast Cancer</i> , 2011 , 11, 82-92	3	99
26	New omics information for clinical trial utility in the primary setting. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 128-33	4.8	4
25	"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 599-606	4.4	43
24	The treatment of individual patients is more than a trial. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 53-4	4.8	2
23	Positron emission tomography and neoadjuvant therapy of breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 111-5	4.8	5
22	Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 67-70	4.8	4
21	Intermediate endpoints of primary systemic therapy in breast cancer patients. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 142-6	4.8	8
20	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 147-51	4.8	55
19	Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 99-102	4.8	6
18	Synergistic activity of letrozole and sorafenib on breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 79-88	4.4	32
17	Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 795-804	4.4	11
16	Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. <i>Clinical Cancer Research</i> , 2009 , 15, 1046-51	12.9	106
15	Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 227-34	2.2	98
14	The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. <i>Cancer Research</i> , 2009 , 69, 4415-23	10.1	234
13	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. <i>Biochemical Pharmacology</i> , 2009 , 78, 460-8	6	61
12	Down-regulation of phosphatidylinositol 3Kkinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2673-80	12.9	49

11	Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. <i>Oncologist</i> , 2008 , 13, 1137-48	5.7	28
10	Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 550-8	12.9	12
9	The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. <i>Bone</i> , 2007 , 40, 182-8	4.7	22
8	Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4562-8	12.9	198
7	Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3623-8	2.2	156
6	Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. <i>Endocrine-Related Cancer</i> , 2006 , 13, 921-30	5.7	60
5	EGFR genotyping in pleural fluid specimens in NSCLC patients. <i>Lung Cancer</i> , 2006 , 54, 265-6	5.9	3
4	Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis 2006 , 671-704		
3	Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. <i>Cancer Research</i> , 2005 , 65, 8690-7	10.1	288
2	Is pathologic complete response a valid surrogate parameter of treatment efficacy in HER2 positive breast cancer patients undergoing primary chemotherapy plus trastuzumab?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8130-1; author reply 8131-2	2.2	2
1	Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2004 , 85, 211-8	4.4	27